Antiretroviral therapy (ART) has evolved considerably over the past three decades. With many antiretroviral (ARV) drugs, combinations and classes available, health care providers have multiple choices regarding ARV therapy. In recent years, significant progress has been made in the treatment of HIV, but many clinicians who manage patients infected with HIV are not aware of the full range of complex and emerging treatment options available or how to apply them to various patient scenarios. Due to the rapidly changing landscape in HIV management, this situation can significantly affect the treatment of patients with HIV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality, and treatment costs.
The HIV Virtual Patient program is an interactive, case-based program featuring real-world case scenarios discussed by HIV thought leaders. Participants will be asked to assess and treat a variety of HIV-positive and HIV-negative patient types with the direction and consultation of HIV thought leaders. This program provides important information that can be directly applied to clinical practice, thereby increasing the delivery of optimal care to patients with HIV infection in the United States.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
After completing this activity, participants should be better able to:
Release Date: April 24, 2019
Expiration Date: April 24, 2020
Media: Internet
Estimated time to complete each Virtual Patient Case: 30-60 minutes
|
Joseph Eron, MD |
Ian Frank, MD Professor of Medicine Director, Clinical Therapeutics Program Penn Center for AIDS Research at the University of Pennsylvania Philadelphia, Pennsylvania |
| W. David Hardy, MD Adjunct Professor of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Washington, DC |
Helena Kwakwa, MD, MPH Director HIV Clinical Services Philadelphia Department of Public Health Ambulatory Health Services Philadelphia, Pennsylvania |
| Michael Sension, MD Medicial Director CAN Community Health Ft. Lauderdale, Florida |
Pablo Tebas, MD Professor of Medicine Hospital of the University of Pennsylvania Director, Adult AIDS Clinical Trials Unit (ACTU) Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania |
| David A. Wohl, MD Professor Division of Infectious Diseases The University of North Carolina at Chapel Hill Chapel Hill, North Carolina |
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Case 1 (HCV-HIV Co-Infection):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Case 2 (HIV and Aging, Treatment-Naive):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Case 3 (First-Line Failure with Resistance):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Case 4 (On PrEP, Recently Diagnosed with HIV):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Case 5 (PrEP and Treatment as Prevention):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Case 6 (HIV and Aging, Treatment-Experienced with NAFLD/NASH):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Joseph Eron, MD
Ian Frank, MD
W. David Hardy, MD
Helena Kwakwa, MD, MPH
Michael Sension, MD
Pablo Tebas, MD
David A. Wohl, MD
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The PIM planners and managers have nothing to disclose.
There are no fees for participating and receiving CME/CE credit for this activity. During the period, April 24, 2019 through April 24, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 14092. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
